Denali Therapeutics Inc. Payments of Stock Issuance Costs
Denali Therapeutics Inc. (DNLI) reported Payments of Stock Issuance Costs of $480.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2025-11-06
- Denali Therapeutics Inc. payments of stock issuance costs for the quarter ending 2024-09-30 was $0.00.
- Denali Therapeutics Inc. payments of stock issuance costs for the quarter ending 2024-06-30 was $0.00.
- Denali Therapeutics Inc. payments of stock issuance costs for the quarter ending 2024-03-31 was $480.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month |
|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $480.00K 10-Q · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $480.00K 10-Q · filed 2025-08-11 | |
| 2024-03-31 | $480.00K 10-Q · filed 2025-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |